Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

American Journal of Cardiology

Volumn 99, Issue 12 SUPPL., 2007, Pages

  Gerstein, Hertzel C ^a   Riddle, Matthew C ^b   Kendall, David M ^c   Cohen, Robert M ^d   Goland, Robin ^e   Feinglos, Mark N ^f   Kirk, Julienne K ^g   Hamilton, Bruce P ^h   Ismail Beigi, Faramarz ⁱ   Feeney, Patricia ^g  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c INTERNATIONAL DIABETES CENTER   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g WAKE FOREST SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; REPAGLINIDE; ROSIGLITAZONE;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES EDUCATION; DRUG DOSE INCREASE; E-MAIL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR;

BLOOD GLUCOSE; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS;

EID: 34250714841     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.03.004     Document Type: Article

References (18)

1. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
2. 1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141 (2004) 413-420
3. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., and Golden S.H. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
4. Coutinho M., Gerstein H.C., Wang Y., and Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22 (1999) 233-240
5. European Diabetes Epidemiology Group DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?. Diabetes Care 26 (2003) 688-696
6. Gerstein H.C. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med 141 (2004) 475-476
7. Khaw K.T., Wareham N., Luben R., Bingham S., Oakes S., Welch A., and Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322 (2001) 1-6
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
9. Abraira C., Colwell J.A., Nuttall F., Sawin C.T., Henderson W., Comstock J.P., Emanuele N.V., Levin S.R., Pacold I., and Lee H.S. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility trial. Arch Intern Med 157 (1997) 181-188
10. Stratton I.M., Adler A.I., Neil A.W., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R., and UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
11. Cryer P.E. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 45 (2002) 937-948
12. Leese G.P., Wang J., Broomhall J., Kelly P., Marsden A., Morrison W., Frier B.M., Morris A.D., and DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26 (2003) 1176-1180
13. Bonds D.E., Kurashige E.M., Bergenstal R., Brillon D., Domanski M., Felicetta J.V., Fonseca V.A., Hall K., Hramriak I., Miller M.E., Osei K., Simons-Morton D.G., and ACCORD Study Group. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 99 suppl (2007) 80i-89i
14. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 99 suppl (2007) 21i-33i
15. 1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients. Diabetes Care 22 (1999) 1785-1789
16. 1c levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes 50 (2001) 2858-2863
17. 1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care 27 (2004) 1259-1264
18. 1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care 26 (2003) 163-167